

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jinxin Fertility Group Limited

錦欣生殖醫療集團有限公司*

(Incorporated under the laws of the Cayman Islands with limited liability)

(Stock Code: 1951)

**VOLUNTARY ANNOUNCEMENT
UPDATES ON THE SHENZHEN AND UNITED STATES OPERATIONS
FOR THE FIRST TWO MONTHS OF 2026**

This is a voluntary announcement made by Jinxin Fertility Group Limited (the “**Company**”) to keep the shareholders of the Company and potential investors informed of the latest business developments of the Company and its subsidiaries (the “**Group**”).

The board of directors (the “**Board**”) of the Company is pleased to announce that the new campus of the Group’s Shenzhen Zhongshan Obstetrics and Gynecology Hospital has commenced trial operations since February 6, 2026. The new facility is located in Shenzhen’s central area and boasts a gross floor area of 40,000 square meters, approximately four times the size of the original campus. The new campus provides a solid foundation to support the sustained business growth of the Shenzhen Zhongshan Obstetrics and Gynecology Hospital, while also enabling the hospital’s expansion into specialized services including VIP services, distinctive specialties and an international medical department. In conjunction with the opening of the new campus, the Group’s Shenzhen operations have maintained strong business growth momentum and witnessed an 18% growth in oocyte pick up cycles (“**OPU Cycles**”) for the first two months of 2026 as compared to the corresponding periods of 2025.

In the United States, the HRC Fertility clinics controlled by the Group through management service agreements saw an increase of approximately 38% in terms of OPU cycles during the first two months of 2026 compared to the corresponding period in 2025. This growth is primarily attributable to the increased demand from local patients following the official implementation of California’s IVF insurance coverage under Senate Bill 729 (the “**SB729**”) in January 2026, which had been postponed from its original planned implementation in about July 2025. Under the SB729, large-corporate health insurance plans (i.e., covering over 100 employees) are required to provide coverage for infertility diagnosis and treatment, and on the other hand, small and medium-sized employers have the option to voluntarily participate. The coverage includes three completed OPU cycles and unlimited embryo transfer cycles, while prohibiting differential treatment based on marital status or other conditions.

The Company remains committed to advancing operational optimization initiatives while continuously enhancing clinical efficacy, and will prioritize improving patient care and service quality, and accelerate the development and upgrade of its core reproductive technologies. Through these efforts, the Company aims to deliver sustainable, long-term value to shareholders and contribute to the high-quality growth of the industry.

The Company wishes to provide its shareholders and potential investors with a business update and the information contained herein is based on a preliminary assessment of the Group and the information currently available to the Company and is not based on any figure or information which has been audited or reviewed by the auditor of the Company. The above figures contained in this announcement are for illustrative purposes only, and do not constitute forward-looking statements or profit numbers.

Shareholders and potential investors of the Company are reminded to rationally deal with any information not officially released by the Company, and shareholders and potential investors of the Company should exercise caution when dealing in the shares of the Company.

By order of the Board
Jinxin Fertility Group Limited
Dong Yang
Chief Executive Officer,
Acting Chief Financial Officer
and Executive Director

Hong Kong, March 4, 2026

As at the date of this announcement, the board of directors of the Company comprises Mr. Dong Yang, Ms. Lyu Rong and Dr. Geng Lihong, as executive Directors; Mr. Zhong Yong, as Chairman and non-executive Director, and Ms. Hu Zhe, Ms. Yan Xiaoqing and Mr. Chen Shuyun, as non-executive Directors; and Dr. Chong Yat Keung, Mr. Li Jianwei, Mr. Wang Xiaobo and Mr. Ye Changqing, as independent non-executive Directors.

* *For identification purposes only*